Dengue virus 4: the ‘black sheep’ of the family?

References

• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013 Apr 25;496(7446):504–507.
   PubMed Web of Science ®Google Scholar
• Halstead S. Dengue. First ed. London: Imperial College Press; 2008.
   Google Scholar
• AB SABIN. Research on dengue during world war II. Am J Trop Med Hyg. 1952. 1. Jan(1):30–50.
   Google Scholar
• Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. 2002 Mar;66(3):264–272.
   PubMed Web of Science ®Google Scholar
• Simasathien S, Thomas SJ, Watanaveeradej V, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg. 2008 Mar;78(3):426–433.
   PubMed Web of Science ®Google Scholar
• Simmons M, Murphy GS, Hayes CG. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg. 2001 Aug;65(2):159–161.
   PubMed Web of Science ®Google Scholar
• Clements DE, Coller BA, Lieberman MM, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine. 2010 Mar 24;28(15):2705–2715.
   PubMed Web of Science ®Google Scholar
• Leng CH, Liu SJ, Tsai JP, et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009 Feb;11(2):288–295.
   PubMed Web of Science ®Google Scholar
• Etemad B, Batra G, Raut R, et al. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg. 2008 Sep;79(3):353–363.
   PubMed Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015 Jan 8;372(2):113–123.
   PubMed Web of Science ®Google Scholar
• Edelman R, Wasserman SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):48–60.
   PubMed Web of Science ®Google Scholar
• Suzarte E, Gil L, Valdes I, et al. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys. Int Immunol. 2015;27(8):367–379.
   PubMed Web of Science ®Google Scholar
• Lazo L, Zulueta A, Hermida L, et al. Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem. 2009 Apr;52(Pt 4):265–271.
   PubMedGoogle Scholar
• Manoff SB, Sausser M, Falk RA, et al. Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naive adults. Hum Vaccin Immunother. 2019;15(9):2195–2204.
   PubMed Web of Science ®Google Scholar
• Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine. 2000 May 26;18(Suppl 2):44–47.
   PubMedGoogle Scholar
• Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J. 2004 Feb;23(2):99–109.
   PubMed Web of Science ®Google Scholar
• Watanaveeradej V, Gibbons RV, Simasathien S, et al. Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial. Am J Trop Med Hyg. 2014 Jul 2;91(1):119–128.
   PubMed Web of Science ®Google Scholar
• Watanaveeradej V, Simasathien S, Mammen MP Jr., et al. Long-term safety and immunogenicity of a tetravalent live-attenuated dengue vaccine and evaluation of a booster dose administered to healthy thai children. Am J Trop Med Hyg. 2016 Jun 1;94(6):1348–1358.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3ʹ-untranslated region. Am J Trop Med Hyg. 2001 Nov;65(5):405–413.
   PubMed Web of Science ®Google Scholar
• Osorio JE, Brewoo JN, Silengo SJ, et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in cynomolgus macaques. Am J Trop Med Hyg. 2011 Jun;84(6):978–987.
   PubMed Web of Science ®Google Scholar
• Rupp R, Luckasen GJ, Kirstein JL, et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study. Vaccine. 2015 Nov 17;33(46):6351–6359.
   PubMed Web of Science ®Google Scholar
• Biswal S, Borja-Tabora C, Martinez VL, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet. 2020 Mar;395(10234):1423-1433.
   PubMedGoogle Scholar
• Durbin AP, Whitehead SS, McArthur J, et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis. 2005 Mar 1;191(5):710–718.
   PubMed Web of Science ®Google Scholar
• Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the sanofi-pasteur CYD vaccine? Expert Rev Vaccines. 2016;15(4):509–517.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Yoon IK. A review of Dengvaxia(R): development to deployment. Hum Vaccin Immunother. 2019;15(10):2295–2314.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014 Oct 11;384(9951):1358–1365.
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012 Nov 3;380(9853):1559–1567.
   PubMed Web of Science ®Google Scholar
• Simmons M, Murphy GS, Kochel T, et al. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am J Trop Med Hyg. 2001 Nov;65(5):420–426.
   PubMed Web of Science ®Google Scholar
• Fonseca BA, Khoshnood K, Shope RE, et al. Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the Escherichia coli trpE gene. Am J Trop Med Hyg. 1991 May;44(5):500–508.
   PubMed Web of Science ®Google Scholar
• Srivastava AK, Putnak JR, Warren RL, et al. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine. 1995 Sep;13(13):1251–1258.
   PubMed Web of Science ®Google Scholar
• Suzarte E, Marcos E, Gil L, et al. Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol. 2014 Jul;159(7):1629–1640.
   PubMed Web of Science ®Google Scholar
• Lazo L, Izquierdo A, Suzarte E, et al. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus. Microbiol Immunol. 2014 Apr;58(4):219–226.
   PubMed Web of Science ®Google Scholar
• Suzarte E, Gil L, Valdes I, et al. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys. Int Immunol. 2015 Aug;27(8):367–379.
   PubMed Web of Science ®Google Scholar
• Kulkarni A, Bhat R, Malik M, et al. Neutralizing antibody response and efficacy of novel recombinant tetravalent dengue DNA vaccine comprising envelope domain III in mice. Iran J Med Sci. 2017 Mar;42(2):152–160.
   PubMed Web of Science ®Google Scholar
• Fahimi H, Sadeghizadeh M, Hassan ZM, et al. Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice. Excli J. 2018;17:1054–1068.
   PubMed Web of Science ®Google Scholar
• Dengue type 4 infections in U.S. Travelers to the Caribbean. MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):249–250.
   PubMedGoogle Scholar
• Chungue E, Cassar O, Drouet MT, et al. Molecular epidemiology of dengue-1 and dengue-4 viruses. J Gen Virol. 1995 Jul;76(Pt 7):1877–1884.
   PubMedGoogle Scholar
• Lanciotti RS, Gubler DJ, Trent DW. Molecular evolution and phylogeny of dengue-4 viruses. J Gen Virol. 1997 Sep;78(Pt 9):2279–2284.
   PubMedGoogle Scholar
• Henchal EA, Repik PM, McCown JM, et al. Identification of an antigenic and genetic variant of dengue-4 virus from the Caribbean. Am J Trop Med Hyg. 1986 Mar;35(2):393–400.
   PubMed Web of Science ®Google Scholar
• Rossi SL, Nasar F, Cardosa J, et al. Genetic and phenotypic characterization of sylvatic dengue virus type 4 strains. Virology. 2012 Feb 5;423(1):58–67.
   PubMed Web of Science ®Google Scholar
• Gallichotte EN, Baric TJ, Nivarthi U, et al. Genetic variation between dengue virus type 4 strains impacts human antibody binding and neutralization. Cell Rep. 2018 Oct 30;25(5):1214–1224.
   PubMed Web of Science ®Google Scholar
• Westaway EG, Blok J. Taxonomy and evolutionary relationships of flaviviruses. In: Gubler D, Kuno G, editors. Dengue and dengue hemorrhagic fever. CAB International, London, UK; 1997. p. 147–173.
   Google Scholar
• UK N, Kose N, Sapparapu G, et al. Mapping the human memory B cell and serum neutralizing antibody responses to dengue virus serotype 4 infection and vaccination. J Virol. 2017 Mar 1;91(5):e02041-16.
   Google Scholar
• Henein S, Swanstrom J, Byers A, et al. Dissecting Antibodies Induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals. J Infect Dis. 2016 Dec 8;215(3):351-358.
   Web of Science ®Google Scholar
• Hadinegoro SR. The revised WHO dengue case classification: does the system need to be modified? Paediatr Int Child Health. 2012 May;32(Suppl 1):33–38.
   PubMedGoogle Scholar
• Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol. 1984 Nov;120(5):653–669.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri G, Valdes L, et al. Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am J Epidemiol. 2000 Nov 1;152(9):793–799.
   PubMed Web of Science ®Google Scholar
• Vaughn DW. Invited commentary: dengue lessons from Cuba. Am J Epidemiol. 2000 Nov 1;152(9):800–803.
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000 Jan;181(1):2–9.
   PubMed Web of Science ®Google Scholar
• Soo KM, Khalid B, Ching SM, et al. Meta-analysis of dengue severity during infection by different dengue virus serotypes in primary and secondary infections. PLoS One. 2016;11(5):e0154760.
   PubMed Web of Science ®Google Scholar
• Fried JR, Gibbons RV, Kalayanarooj S, et al. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis. 2010;4(3):Mar.
   Web of Science ®Google Scholar
• Althouse BM, Durbin AP, Hanley KA, et al. Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis. Virology. 2014 Mar;452-453:237–246.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol. 2010;338:129–143.
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Barrett AD. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology. 2007 Sep 30;366(2):349–360.
   PubMed Web of Science ®Google Scholar
• Fu J, Tan BH, Yap EH, et al. Full-length cDNA sequence of dengue type 1 virus (Singapore strain S275/90). Virology. 1992 Jun;188(2):953–958.
   PubMed Web of Science ®Google Scholar
• Venkatachalam R, Subramaniyan V. Homology and conservation of amino acids in E-protein sequences of dengue serotypes. Asian Pac J Trop Disease. 2014 Sep;4(Suppl 2):S573–S577.
   Google Scholar
• Volk DE, Lee YC, Li X, et al. Solution structure of the envelope protein domain III of dengue-4 virus. Virology. 2007 Jul 20;364(1):147–154.
   PubMed Web of Science ®Google Scholar
• Kostyuchenko VA, Chew PL, Ng TS, et al. Near-atomic resolution cryo-electron microscopic structure of dengue serotype 4 virus. J Virol. 2014 Jan;88(1):477–482.
   PubMed Web of Science ®Google Scholar
• Sukupolvi-Petty S, Brien JD, Austin SK, et al. Functional analysis of antibodies against Dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol. 2013 Jun;87(16):8826-8842.
   Web of Science ®Google Scholar
• Swanstrom JA, Nivarthi UK, Patel B, et al. Beyond neutralizing antibody levels: the epitope specificity of antibodies induced by National Institutes of Health monovalent dengue virus vaccines. J Infect Dis. 2019 Jun 19;220(2):219–227.
   PubMed Web of Science ®Google Scholar
• Putnak JR, de la BR, Burgess T, et al. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg. 2008 Jul;79(1):115–122.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Nisalak A, Anderson KB, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg. 2009 Nov;81(5):825–833.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Dowd KA, Manhart CJ, et al. The mechanism and significance of cell type-dependent neutralization of flaviviruses. J Virol. 2014 Apr;88(13):7210-7220.
   Web of Science ®Google Scholar
• Porterfield JS. Antibody-dependent enhancement of viral infectivity. Adv Virus Res. 1986;31:335–355.
   PubMed Web of Science ®Google Scholar
• Zellweger RM, Miller R, Eddy WE, et al. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. 2013 Oct;9(10):e1003723.
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008 Jun;21(2):123–132.
   PubMed Web of Science ®Google Scholar
• Sukupolvi-Petty S, Brien JD, Austin SK, et al. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol. 2013 Aug;87(16):8826–8842.
   PubMed Web of Science ®Google Scholar